Market Research Logo

Pulmonary Hypertension - Global Market Research 2015-2019

About pulmonary hypertension

Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

Technavio's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Technavio's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion
  • Bayer
  • GlaxoSmithKline
  • United Therapeutics
Other prominent vendors
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Bial
  • DEKA
  • Dong-A ST
  • Gilead
  • Merck
  • Northern Therapeutics
  • Novartis
  • Pfizer
  • PhaseBio
Key market driver
  • Growing incidence of pulmonary hypertension
  • For a full, detailed list, view our report
Key market challenge
  • Patent expiry
  • For a full, detailed list, view our report
Key market trend
  • Increased focus on combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Pulmonary Hypertension Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Pulmonary Hypertension Market: Actelion, Bayer, GlaxoSmithKline and United Therapeutics

Other Prominent Vendors in the market are: Aires Pharmaceuticals, Arena Pharmaceuticals, Bial, DEKA, Dong-A ST, Gilead, Merck, Northern Therapeutics, Novartis, Pfizer, PhaseBio, Radikal Therapeutics, Reata Pharmaceuticals, and SteadyMed.

Commenting on the report, an analyst from Technavio’s team said: “The hypertension treatment is shifting toward the use of combination therapies that employ two or more drugs. Combination therapy with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure at a faster pace, help in obtaining target blood pressure, and decrease adverse effects. The treatment is also aimed at targeting various disease mechanisms that may result in better outcomes.”

According to the report, the median survival for a person living with pulmonary hypertension is only five to six years. In addition, the current treatments do not target the underlying cause of the disorder. Thus, the disorder treatment is associated with poor patient compliance. Hence, patients often discontinue the treatment without completing the treatment cycle. Other classes (or types) of medications used to treat pulmonary hypertension also have side effects. Therefore, current treatment options result in unmet medical needs that warrant the development of new drugs with better safety and efficacy, thereby driving the market.

Further, the report states that patent expiry of drugs such as Revatio is hindering the market growth by allowing low-cost generics to enter the market. Poor patient compliance during treatment due to the adverse effects of the drugs used is also impeding the market growth.



Companies Mentioned

Actelion, Bayer, GlaxoSmithKline, United Therapeutics, Aires Pharmaceuticals, Arena Pharmaceuticals, Bial, DEKA, Dong-A ST, Gilead, Merck, Northern Therapeutics, Novartis, Pfizer, PhaseBio, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global pulmonary hypertension market: 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline portfolio
    • Table Pipeline portfolio
    • Key information of pipeline candidates
  • Market segmentation by type of formulation
    • Table Market segmentation by type of formulation
    • Oral
    • Injection
    • Inhalation
      • Table Market segmentation by type of formulation 2014
  • Market segmentation by mechanism of action
    • Table Market segmentation by mechanism of action
    • Endothelin receptor antagonist
    • Prostacyclin analogs
    • Phosphodiesterase inhibitors
    • Soluble guanylate cyclase stimulators
      • Table Market segmentation by mechanism of action 2014
  • Geographical segmentation
    • Table Market segmentation by region 2014
  • Market drivers
    • Increase in incidence of pulmonary hypertension
    • Patient assistance programs
    • New disease-modifying therapies
    • Unmet medical needs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Patent expiry
      • Table Revatio sales in the US 2011-2014 ($ millions)
    • Poor patient compliance
    • Intense competition among vendors
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increased focus on combination therapies
    • Increase in awareness of hypertension
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Key news
    • Mergers and acquisitions
    • Market share analysis 2014
      • Table Actelion Pharmaceuticals : Key takeaways
      • Table Tracleer: Global sales 2011-2014 ($ billions)
      • Table Opsumit: Global sales 2013-2015 H1 ($ millions)
      • Table Ventavis: Global sales 2011-2014 ($ millions)
      • Table Veletri: Global sales 2011-2014 ($ millions)
      • Table United Therapeutics: Key takeaways
      • Table Remodulin: Global sales 2011-2014 ($ millions)
      • Table Tyvaso: Global sales 2011-2014 ($ millions)
      • Table Adcirca: Global sales 2011-2014 ($ millions)
      • Table Orenitram: Global sales 2014-2015 H2 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
      • Table Flolan: Global sales 2012-2013 ($ millions)
      • Table Bayer: Key takeaways
      • Table Adempas: Global sales 2013-2014 ($ millions)
    • Other prominent vendors
  • Key vendor analysis
    • Actelion Pharmaceuticals
      • Table Actelion Pharmaceuticals: Product segmentation
      • Table Actelion Pharmaceuticals: Business segmentation by revenue 2014
      • Table Actelion Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
      • Table Actelion Pharmaceuticals: Geographical segmentation by revenue 2014
    • Bayer HealthCare
    • GSK
    • United Therapeutics
      • Table United Therapeutics: Product segmentation by revenue 2014
      • Table United Therapeutics: Product segmentation by revenue 2014 ($ millions)
      • Table United Therapeutics: Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report